Video
Neurotech platform delivers biological agent over extended period to slow progression of retinal-based diseases
Author(s):
Rich Small, CEO of Neurotech, provides updates on the company’s pipeline that is the culmination of nearly 2 decades of research.
Rich Small, CEO of Neurotech, provides updates on the company’s pipeline that is the culmination of nearly 2 decades of research with Sheryl Stevenson, Ophthalmology Times®’ Group Editorial Director, during the New Horizons Forum at the 2022 Glaucoma 360 meeting
Related Videos
Related Content
